Abstract:Mari Tone 1,2 , Kota Iwahori 1,2 1 Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; 2 Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan Comment on: Rotolo R, Leuci V, Donini C, et al . Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. Clin Cancer Res 2023;29:621-34. Keywords: Anti programmed death-1 antibody (anti-PD-1 antibody); cancer stemness; non-small cell lung cancer (NSCLC); chemoresistance Submitted Oct 23, 2023. Accepted for publication Jan 05, 2024. Published online Jan 25, 2024. doi: 10.21037/tlcr-23-683 In this editorial commentary, we discussed the potential of programmed death-1 (PD-1) expression on tumor cells as a novel target for the treatment of non-small cell lung cancer (NSCLC) patients based mainly on the findings reported by Rotolo and colleagues (1). We focused on PD-1 expression on tumor cells as a biomarker for combination chemotherapy with anti-PD-1 antibodies and cytotoxic agents as well as future perspectives for PD-1 targeted cancer therapy ( Figure 1 ). Anti-PD-1 blockade is one of the most frequently used immune checkpoint inhibitors in multiple settings, including monotherapy, combination therapy with cytotoxic agents (2), neoadjuvant therapy (3), and post-chemoradiation therapy (4), for patients with NSCLC. While the most common mechanism for the anti-tumor effects of anti-PD-1 blockade is an increase in T cell activity in the tumor microenvironment (5-7), a lymphocyte-independent function was recently reported in melanoma (8-10). Kleffel and colleagues reported that human melanoma tumor tissues frequently contained PD-1-expressing tumor cell subsets. Moreover, an anti-PD-1 antibody inhibited lymphocyte-independent tumor growth in murine models via the mTOR pathway (8). Sanlorenzo and colleagues demonstrated that BRAF and MEK inhibitors increased the number of PD-1-positive melanoma cells, indicating the potential of lymphocyte-independent synergism with anti-PD-1 antibodies (9). In the study that is the focus of this editorial commentary, Rotolo and colleagues reported the novel lymphocyte-independent anti-tumor efficacy of an anti-PD-1 antibody in human and murine NSCLC cell lines (1). The baseline expression of PD-1 in NSCLC cell lines was low and increased after the administration of cisplatin. PD-1 expression was enhanced in stem-like NSCLC pneumospheres, derived from NSCLC cell lines cultured within a defined serum-free medium, exhibiting characteristics reminiscent of stem cells. The anti-PD-1 antibody showed lymphocyte-independent anti-tumor efficacy in vitro and in vivo , and its combination with cisplatin exerted synergistic anti-tumor effects. A question refers to the variance in downstream signaling of PD-1 observed between T cells and tumor cells. Anti-PD1 antibody blocks the growth of PD-1-positive tumor cells, but not PD-1-expressing T cells. Comparison of downstream signaling of PD-1 between T cells and tumor cells will clarify the rational of anti-PD-1 therapy. The study by Rotolo and colleagues focused on the expression of PD-1, not programmed death-ligand 1 (PD-L1), in NSCLC cells. PD-L1 is currently used as a biomarker to predict the efficacy of anti-PD-1 antibody therapy for NSCLC patients (11,12), whereas PD-1 expression has not been reported to be a predictive biomarker of anti-PD-1 treatment outcome in clinical settings. A critical issue for NSCLC patients without driver mutations is that there are currently no useful biomarkers for combination therapy with anti-PD-1 antibodies and cytotoxic agents. PD-L1 expression is not used as a biomarker for the combination therapy with anti-PD-1 antibodies. The findings obtained by Rotolo and colleagues suggested that PD-1-positive NSCLC cells exhibited resistance to cytotoxic chemotherapy. Anti-PD-1 may be used more effectively when NSCLC relapses after the administration of cytotoxic agents for NSCLC highly expressing PD-1. The study by Rotolo and colleagues showed that the concurrent combination of an anti-PD-1 antibody with cisplatin exerted synergistic lymphocyte-independent effects on NSCLC in vivo . The synergistic effects of the combination of anti-PD-1 antibodies with cytotoxic agents have been attributed to immunogenic cell death induced by cytotoxic agents (13). On the other hand, the findings of lymphocyte-independent experiments conducted by Rotolo and colleagues provide a novel viewpoint of anti-PD-1 providing additional efficacy to cytotoxic agents by targeting PD-1-positive NSCLC cells. Therefore, PD-1 expression on NSCLC cells has potential as a predictive biomarker for the efficacy of anti-PD-1 therapy with cytotoxic ag -Abstract Truncated-

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

Immu-02. Intracranial Progression Is Less Common In Patients With Advanced Nsclc Receiving Cancer Immunotherapy

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies

PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy

1241 Sustained Localized Delivery of Anti-PD-1 to Tumor Draining Lymph Nodes Increases Survival and Reverses Immunosuppression in Murine Glioblastoma Models

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Safety, Efficacy, and Biomarker Analysis of Response to Engineered Tumor-Infiltrating Lymphocytes Secreting Anti-Pd-1 Antibody in Recurrent Glioblastoma: an Open-Label, Two-Arms, Phase 1 Study

Clinical analysis of programmed death-1 inhibitor in treatment of patients relapsed/refractory diffuse large B-cell lymphoma with central nervous system involvement and literature review

Anti-PD-(L)1 Immunotherapy for Brain Metastases in Non-Small Cell Lung Cancer: Mechanisms, Advances, and Challenges.

Abstract 6335: Armoring CAR-T therapy with PD-1 blockade: a powerful strategy for enhancing anti-tumor effects in pancreatic cancer

Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking

Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients

PD-1 expression on tumor cells: a new target for cancer therapy

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system

PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

Abstract LB071: Weaponizing CAR T-cells to attack PD-L1 presenting cells in solid tumors

Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?